Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5030027 | 1.00 | ATM (0.41) | ATMTDP1L3MBTL1ALOX15ALDH1A1 | |
| SCHEMBL7930882 | 0.83 | ALOX15 (0.49) | ATMTDP1L3MBTL1ALOX15ALDH1A1 | |
| SCHEMBL11446111 | 0.83 | CA1 (0.44) | ATMTDP1L3MBTL1CA1CA2 | |
| SCHEMBL11445079 | 0.82 | ATM (0.43) | ATMTDP1L3MBTL1ALOX15ALDH1A1 | |
| SCHEMBL13839552 | 0.77 | TSHR (0.47) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL3883464 | 0.77 | TSHR (0.47) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL27694653 | 0.76 | CA1 (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL14606537 | 0.76 | TRPA1 (0.39) | CA1CA2CA7CA9TSHR | |
| SCHEMBL3441033 | 0.75 | CA1 (0.40) | CA1CA2CA7CA9TSHR | |
| SCHEMBL3441037 | 0.75 | CA1 (0.40) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931324-B1 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RES FOUND (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-1931324-B1 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RES FOUND (US) | 2015-01-28 | — | — | EP | disclosed |
| US-7534777-B2 | Des-C,D analogs of 1α,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534777-B2 | Des-C,D analogs of 1α,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534777-B2 | Des-C,D analogs of 1α,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1931324-A2 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-17 | — | — | US | disclosed |
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-17 | — | — | US | disclosed |
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-17 | — | — | US | disclosed |
| WO-2007028000-A2 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028000-A2 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | CYP24A1, VDR, CYP2R1 | ATM 4725/4885TDP1 3849/4885L3MBTL1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.